NEW
YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/biomea-fusion-class-action-loss-submission-form/?id=41804&from=4
Further details on the investigation: On June 23, 2023, Biomea Fusion presented data for
its Type 2 diabetes drug candidate BMF-219 at a meeting of the
American Diabetes Association. In response to the presentation,
market analysts downgraded Biomea Fusion and its stock price fell
$6.25 per share, from $30.67 per share on June
23, 2023 to close at $24.42
per share on June 26, 2023.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/bmea-fraud-alert-jakubowitz-law-is-investigating-biomea-fusion-inc-in-connection-with-potential-violations-of-federal-securities-laws-301871615.html
SOURCE Jakubowitz Law